A study of drugs plus radiation for early-stage NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial tests a combination of the drugs dexamethasone, azacitidine, pegaspargase, and tislelizumab along with radiation therapy for people with stage I or II extranodal NK/T-cell lymphoma. The goal is to see if this treatment works well and is safe for patients who have not yet received treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with extranodal NK/T-cell lymphoma (a type of lymphoma affecting the nose, throat, or other areas).
- You must be at least 18 years old.
- Your cancer must be stage I or II (limited to one area or nearby lymph nodes).
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (ECOG score 0 to 2).
- Your blood cell counts must be within certain ranges (neutrophils, platelets, and hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immune checkpoint inhibitor) as the first treatment for advanced extranodal natural killer/T-cell lymphoma. The goal is to see if this combination can shrink or eliminate the cancer and improve outcomes.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
This trial compares two treatment combos for newly diagnosed, advanced NKTCL. It tests a new combination (chidamide plus an immunotherapy drug and pegaspargase) against a standard regimen (DDGP) to see which works better and is safe.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.